Abstract
Introduction

In human and murine spleen, two main classes of dendritic cells (DC) are present: conventional (c)DC and plasmacytoid (p)DC.
These are distinct in terms of cytokine production, cross-presentation capacity and T helper response generated [1, 2] . Conventional [4] produces high levels of interferon (IFN)-␣ upon viral exposure [5] . Further spleen DC subsets in mice derived in vitro loosely fall under the term 'regulatory' DC. These include diffDC [6] , CD11c lo CD11b hi MHC-II lo DC [7] and IL-10 DC [8] . Under inflammatory or infectious settings, myeloid DC in spleen may also include tumour necrosis factor (TNF)/iNOSproducing DC [9] and monocyte-derived DC (mo-DC) [10, 11] . [12] . Although subsets of myeloid cells including monocytes have been described in spleen, this lineage is less well defined in terms of subsets than is the DC lineage [13] .
The latter represent a very different cell type to cDC and pDC, developing under inflammatory conditions which drive cells from blood into lymph nodes for antigen presentation
Most DC subsets present antigen in the context of both MHC-I and MHC-II, and some have a unique ability to cross-present exogenous antigen via MHC-I [14]. Exogenous antigen is normally routed through the MHC-II pathway for presentation to CD4
ϩ T cells [15] . Cytosolic antigens are usually loaded on to MHC-I for CD8
ϩ T-cell activation [16] . However in cross-presentation, exogenous antigens are directed into the MHC-I pathway for recognition by CD8 ϩ T cells. CD8␣ ϩ cDC have been described as the major cross-presenting antigen-presenting cells (APC) subset in spleen [2, 17] . Although some DC are recognized as very potent cross-presenting cells, they are not unique in this role. Reports claim that macrophages/monocytes [18] and neutrophils [19] can cross-present antigen, although their efficiency, and the extent and range of T cells activated are not characterized. [20] . LTC 
Our laboratory has characterized a novel dendritic-like cell type produced in vitro in stroma-dependent long-term cultures (LTC) of spleen
Long-term cultures
LTC were established from spleens of female mice aged 8 days and maintained in supplemented DMEM (sDMEM) as described previously [20] . Non-adherent cells were collected for experimentation from culture flasks at medium change by resuspension of loosely adhered cells. LTC used here were tested clear of mycoplasma contamination using published methodology [24] .
Flow cytometry
Flow cytometry was performed on antibody labelled cells using a Fluorescence Activated Cell Sorter (FACS) to assess cell surface marker expression as described previously [25] . Anti 
Depletion of T and B cells from spleen
Measurement of endocytosis
To assess endocytosis in vitro, FITC-conjugated OVA (OVA-FITC; Molecular Probes) was added to cells and uptake measured flow cytometrically as described previously [25] . Cells (10 6 ) were exposed to OVA-FITC ( 
Antigen-specific T-cell activation by DC
The antigen presenting capacity of DC subsets was assessed using purified 
cells from OT-I T cell receptor (TCR)-tg
Results
LTC-DC display distinct phenotype and function
Cells produced in LTC reflect myeloid lineage DC in that they express CD11c and CD11b but never CD8␣ or B220 (Fig. 1) Fig. 2A) .
High dose inhibition of T-cell proliferation induced by OVA ϩ LPS pulsed LTC-DC was likely caused by cell death in cultures, because strong activation of T cells by high numbers of LTC-DC was mirrored in both CD69 up-regulation and IFN-␥ production. CD11c ϩ spleen DC were better activators of CD4 ϩ OT-II T cells than LTC-DC (Fig. 2B). Weak activation of OT-II T cells by LTC-DC was indicated at 4 days, but only with LPS as an activator. This is consistent with minor up-regulation of already negative to low MHC-II expression on LTC-DC following LPS treatment which was reported previ-
ously [21] . (Fig. 3B) . This enhanced response suggests more effective antigen presentation due to LTC-DC participation, and argues against LTC-DC as regulatory DC [6] . (Fig. 4A) . Figure 4 . Both subsets were large in size and highly endocytic for FITC-OVA in vitro (Fig. 4B and C) (Fig. 4C) 
An in vivo LTC-DC counterpart in spleen
Flow cytometric analysis of T cell depleted splenocytes led to identification of an L-DC population not previously identified. Direct comparison of marker expression on L-DC and LTC-DC is shown in
. The prevalence of each subset was estimated after similar cell isolations on seven female C57BL/6J mice. A two-way ANOVA showed no significant (P Յ 0.05) experimental effect, but a significant T-cell subset effect for prevalence of L-DC compared with myeloid cells and CD8
Ϫ cDC (Fig. 4D) 
Fig. 3 Ability of LTC-DC to induce and inhibit an MLR. T cells were purified from CBA/H or C57BL/6J mouse spleen and CFSE labelled. APC included freshly isolated CD11c ϩ spleen DC (f-DC) from CBA/H or C57BL/6J mice, or LTC-DC (B6.SJL origin). (A) Diluting numbers of APC were incubated with T cells (10 5 ) for 4 days. Cells were collected stained with antibody, and analysed flow cytometrically to determine %CD4 ϩ or %CD8 ϩ T cell division based on decrease in CFSE labelling. T cells cultured with no APC gave 0% division (not shown). (B) MLR co-cultures were established as in (A) using a T cell : f-DC ratio of 15:1. Varying numbers of LTC-DC were added into co-cultures to test their ability to inhibit the MLR reaction. Percentage T-cell division was calculated as in (A), and the level achieved in the absence of added LTC-DC is shown as a dashed line. myeloid cells were highly endocytic in situ, with L-DC showing highest uptake of FITC-OVA from blood amongst all subsets analysed (Fig. 5). However, L-DC differed from myeloid cells by higher expression of MHC-I, large size (FSC hi ) and higher endocytic capacity. In common with LTC-DC, L-DC expressed MHC-I, and CD80 but not 33D1, CD205 or ckit. However, LTC-DC differed from L-DC as CD86
Ϫ cells. 
L-DC cross-present antigen for T-cell activation
CD8␣
ϩ cDC are highly cross-presenting cells both in vitro [32] and in vivo [2, 17] Figure 1 
T cells in the presence and absence of LPS as an activator. L-DC were strong activators of OT-I CD8 ϩ T cells but only after LPS activation. The cross-presenting capacity of CD8␣ ϩ cDC was very strong, and increased after activation with LPS (Fig. 6A). The main phenotypic effect of LPS activation on L-DC after culture in vitro maps to up-regulation of CD86, which is not expressed on freshly isolated cells (Fig 5; all data not shown). The capacity of isolated L-DC and CD8␣ ϩ cDC to activate T cells in vivo was compared after adoptive transfer. APC were isolated as in Figure 4, and pulsed with antigen in vitro before intravenous transfer to mice given purified CFSE-labelled OT-I lymphocytes 2 hrs previously. Control mice received only CFSElabelled OT-I lymphocytes and no OVA-pulsed APC. Mice were left for 25 days and then challenged by intravenous administration of OVA (10 mg). Spleens were harvested 9 days later to identify CFSE-labelled T cells. Mice given either OVA-pulsed L-DC or CD8␣ ϩ cDC, showed evidence of division among surviving OT-I T cells (Fig. 6B). There was low survival of OT-I T cells in mice given only OT-I T cells, even following OVA challenge at day 25. This result reinforces L-DC as capable of antigen presentation leading to an immunogenic response in vivo. © 2011 The Authors Journal of Cellular and Molecular Medicine © 2011 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
Fig. 4 Isolation of a spleen in vivo equivalent of LTC-DC (L-DC). Dissociated, RBC-lysed and T cell depleted spleen cells were stained with specific antibodies and PI (1 g/ml) prior to flow cytometric analysis. Endocytic capacity was measured in vitro by uptake of FITC-OVA as described in the
(B) Phenotypic comparison of size (FSC), marker expression and endocytic capacity was made between LTC-DC and L-DC. Shaded histograms indicate isotype control binding (or endocytosis control). (C) In vitro capacity for endocytosis of OVA-FITC was assessed for each gated spleen subset in relation to a non-endocytic control cell population (filled histogram). (D) The prevalence of each of the defined cell subsets was measured in terms of percentage among total spleen leucocytes.
The T-cell stimulatory capacity of splenic L-DC and LTC-DC was also confirmed by activation of allogeneic T cells in a MLR
Discussion
This paper characterizes a novel APC subset produced in vitro which has an in vivo counterpart in murine spleen. A full and CD8␣ ϩ cDC were pulsed with OVA (10 g/ml) and co-cultured with purified CFSE-labelled CD8 ϩ T cells (10 5 ) from OT-I mice ϮLPS (1 g/ml). [36] . (Fig. 3) [6, 7] 
) cells. In order to measure the in situ capacity of cells for endocytosis, mice were given FITC-OVA (3 mg) i.v. 24 hrs prior to isolation of spleen cells for antibody staining and analysis. Endocytosis was assessed for each gated subset in relation to a non-endocytic control spleen lymphocyte population (filled histogram). For LTC-DC, endocytosis was measured after in vitro
Proliferation of cells was measured by dilution of CFSE after 4 days for calculation of percentage divided cells. (B) Isolated L-DC and CD8␣
In terms of their relationship with other subsets, LTC-DC do not have the immunosuppressive properties of regulatory DC
